EGFR and non-small cell lung carcinoma: Aumonertinib (almonertinib), a novel and irreversible third-generation EGFR-TKI, was employed as a second-line treatment of NSCLC patients with the T790M mutation following the progression to EGFR-sensitive mutation therapy [36, 37].